Rethinking High-Grade Serous Ovarian Carcinoma: Development of New Preclinical Animal Models for Evaluation of Image-guided Surgery and Immunotherapy

2017

• Katrin Kleinmanns; Shamundeeswari Anandan; Ida Tveit Karlsen et al. (2017). Engraftement optimization, charaterization and tumor spread tracking by preclinical imaging in ovarian cancer patiant. (ekstern lenke)

2022

• Christiane Helgestad Gjerde; Anika Langer; Gorka Ruiz de Garibay et al. (2022). Establishment of peritoneal dECM scaffolds for 3D culture of ovarian cancer organoids. (ekstern lenke)
• Katrin Kleinmanns; Stein-Erik Gullaksen; Geir Bredholt et al. (2022). Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. (ekstern lenke)
• Christiane Helgestad Gjerde; Anika Langer; Gorka Ruiz de Garibay et al. (2022). Establishment of peritoneal dECM scaffolds for culture of ovarian cancer organoids. (ekstern lenke)
• Maria Grazia Perrone; Paola Vitale; Morena Miciaccia et al. (2022). Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. (ekstern lenke)
• Katrin Kleinmanns; Christiane Helgestad Gjerde; Anika Langer et al. (2022). Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. (ekstern lenke)
• Christiane Helgestad Gjerde; Anika Langer; Gorka Ruiz de Garibay et al. (2022). Establishment of ovarian cancer organoids on peritoneal dECM scaffolds. (ekstern lenke)

2025

• Luka Tandaric; Annika Auranen; Katrin Kleinmanns et al. (2025). Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial. (ekstern lenke)

2021

• Mihaela-Lucia Popa; Vibeke Samuelsen Fosse; Katrin Kleinmanns et al. (2021). Xenograft Models of Ovarian Cancer for Therapy Evaluation. (ekstern lenke)
• Elvira García de Jalón; Katrin Kleinmanns; Vibeke Samuelsen Fosse et al. (2021). Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. (ekstern lenke)
• Christiane Helgestad Gjerde; Anika Langer; Gorka Ruiz de Garibay et al. (2021). Establishment of ovarian cancer organoids on peritoneal dECM scaffolds. (ekstern lenke)
• Shamundeeswari Anandan; Liv Cecilie Vestrheim Thomsen; Stein-Erik Gullaksen et al. (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. (ekstern lenke)

2019

• Katrin Kleinmanns (2019). rethinking high-grade serous ovarian carcinoma: development of new preclinical animal models for evaluation of image-guided surgery and immunotherapy. (ekstern lenke)
• Katrin Kleinmanns; Vibeke Samuelsen Fosse; Ben Davidson et al. (2019). EP889 improved cytoreduction of ovarian cancer using CD24 targeted fluorescence image guided surgery in a preclinical murine model. (ekstern lenke)

2023

• Liv Cecilie Vestrheim Thomsen; Katrin Kleinmanns; Shamundeeswari Anandan et al. (2023). Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study. (ekstern lenke)

2020

• Katrin Kleinmanns; Katharina Bischof; Shamundeeswari Anandan et al. (2020). CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. (ekstern lenke)
• Katrin Kleinmanns; Vibeke Samuelsen Fosse; Line Bjørge et al. (2020). The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. (ekstern lenke)
• Katrin Kleinmanns; Vibeke Samuelsen Fosse; Ben Davidson et al. (2020). CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. (ekstern lenke)

2024

• Cecilie Fredvik Torkildsen; Marie Austdal; Anders Hagen Jarmund et al. (2024). New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients. (ekstern lenke)
• Katrin Kleinmanns; Line Bjørge (2024). Prospects for precision medicine in ovarian cancer.. (ekstern lenke)
• Nicholas Paul Casey; Katrin Kleinmanns; Christopher Forcados et al. (2024). Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin

My project focuses on the development of immunocompetent patient-derived xenograft (PDX) models of ovarian carcinomas to improve therapeutic interventions through novel immune therapies and targeted fluorescence image-guided surgery. These advanced mouse models are additionally reconstituted with a functional human immune system, which replicate the heterogeneities observed in patient tumours whilst also reproducing key features of the human immune system. Immunotherapies, neither immune-checkpoint inhibitor nor chimeric antigen receptor (CAR) T cells, have been shown successful in ovarian carcinomas, yet. Key drivers for my project are the genomic and phenotypic characterization of our established PDX models including the verification of the genomic fidelity to the paired primary tumors as well as the phenotypic deciphering of the complex tumor microenvironment (TME). The aim of my projects is to provide a good and reliable preclinical animal model that combines the interactions of the TME, including human immune system and genomic evolution of tumor cells. I am involved in several collaboration projects focusing on overcoming treatment resistance in ovarian cancer, implementing time-domain fluorescence imaging and testing novel CAR T cell therapies in vivo.